Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Eptifibatide (Integrilin)
Eptifibatide · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Eptifibatide | EXPERIMENTAL | Eptifibatide in addition to standard of care such as standard doses of aspirin, unfractionated heparin or low-molecular-weight heparin. |
| Placebo | PLACEBO_COMPARATOR | Placebo in addition to standard of care such as standard doses of aspirin, unfractionated heparin or low-molecular-weight heparin. |
| Name | Type | Description |
|---|---|---|
| Eptifibatide (Integrilin) | DRUG | intravenous; 180 mcg/kg bolus followed by infusion of 2 mcg/kg/min for 12 to 96 hours (or longer if necessary to complete the 18- to 24-hour post-PCI infusion period, or up to 120 hours in patients who proceed to CABG \[coronary artery bypass graft\]); second bolus of 180 mcg/kg administered 10 minutes after first bolus. |
| Placebo | DRUG | intravenous; delivery to match eptifibatide to maintain blind |
Inclusion Criteria: * Willing and able to give informed consent and comply with study procedures and follow-up through 1 year. * Plan to undergo an invasive strategy after receiving study drug for 12 to 96 hours. * Able to be randomized into the trial within 12 hours of having symptoms of acute cor...
Eptifibatide is used in patients with myocardial ischemia and acute coronary syndrome. It is a small molecule studied for early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome. It is given to adults 18 years and older and is not intended for healthy volunteers.
Eptifibatide targets ITGB3 and ITGA2B, which together form the glycoprotein IIb/IIIa receptor on platelets. It acts as an inhibitor of this receptor, which is the mechanism studied in its cardiovascular program for myocardial ischemia and acute coronary syndrome.
Eptifibatide is developed by Organon & Co., which trades under the ticker OGN. The company is the sponsor associated with the Phase 3 program evaluating the drug in myocardial ischemia and acute coronary syndrome.
Eptifibatide is in Phase 3 development for myocardial ischemia. It is an investigational small molecule and is not described as approved for this use. The Phase 3 trial in the program has completed, and no trials are currently active.
Eptifibatide was studied in the Phase 3 EARLY ACS trial, NCT00089895, titled Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome. That randomized, double-blind, placebo-controlled trial enrolled 9,406 adults and is completed.
Yes, Eptifibatide is also known as Integrilin. Both names refer to the same small molecule developed by Organon & Co. under the ticker OGN, studied as an ITGB3 and ITGA2B inhibitor in myocardial ischemia and acute coronary syndrome.